RecruitingPhase 1Phase 2NCT07224152
NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
Sponsor
M.D. Anderson Cancer Center
Enrollment
40 participants
Start Date
Mar 27, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called NBTXR3 for people with locally advanced non-small cell lung cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNBTXR3
Given by injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07224152
Related Trials
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
NCT060661381 location
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
NCT076323651 location
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
NCT073099521 location
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
NCT071648851 location
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT067347021 location